{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:48:42Z","timestamp":1792064922833,"version":"4.4.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":87,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"DOI":"10.1186\/s12894-026-02264-5","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T12:23:15Z","timestamp":1784550195000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Durable complete metabolic response to enfortumab vedotin plus pembrolizumab in metastatic upper tract urothelial carcinoma: a case report"],"prefix":"10.1186","volume":"26","author":[{"given":"Melike D\u00f6nmez","family":"Tekin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atike P\u0131nar","family":"Erdo\u011fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"\u015eahbazlar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Fara\u015fat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma Seher","family":"Pehlivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferhat","family":"Ekinci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"issue":"1","key":"2264_CR1","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.eururo.2023.03.013","volume":"84","author":"M Roupr\u00eat","year":"2023","unstructured":"Roupr\u00eat M, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update. Eur Urol. 2023;84(1):49\u201364. https:\/\/doi.org\/10.1016\/j.eururo.2023.03.013.","journal-title":"Eur Urol"},{"issue":"5","key":"2264_CR2","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.eururo.2016.11.012","volume":"71","author":"T Seisen","year":"2017","unstructured":"Seisen T, et al. Efficacy of Systemic Chemotherapy Plus Radical Nephroureterectomy for Metastatic Upper Tract Urothelial Carcinoma. Eur Urol. 2017;71(5):714\u20138. https:\/\/doi.org\/10.1016\/j.eururo.2016.11.012.","journal-title":"Eur Urol"},{"issue":"10","key":"2264_CR3","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","volume":"76","author":"PM Challita-Eid","year":"2016","unstructured":"Challita-Eid PM, et al. Enfortumab Vedotin Antibody\u2013Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models. Cancer Res. 2016;76(10):3003\u201313. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-1313.","journal-title":"Cancer Res"},{"issue":"12","key":"2264_CR4","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","volume":"384","author":"T Powles","year":"2021","unstructured":"Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Dur\u00e1n I, Lee JL, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med. 2021;384(12):1125\u201335. https:\/\/doi.org\/10.1056\/NEJMoa2035807.","journal-title":"N Engl J Med"},{"issue":"10","key":"2264_CR5","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles T, et al. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. N Engl J Med. 2024;390(10):875\u201388. https:\/\/doi.org\/10.1056\/NEJMoa2312117.","journal-title":"N Engl J Med"},{"issue":"1","key":"2264_CR6","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1200\/JCO.22.01643","volume":"41","author":"CJ Hoimes","year":"2023","unstructured":"Hoimes CJ, Flaig TW, Milowsky MI, et al. Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer. J Clin Oncol. 2023;41(1):22\u201331. https:\/\/doi.org\/10.1200\/JCO.22.01643.","journal-title":"J Clin Oncol"},{"issue":"29","key":"2264_CR7","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1200\/JCO.19.01140","volume":"37","author":"JE Rosenberg","year":"2019","unstructured":"Rosenberg JE, O\u2019Donnell PH, Balar AV, McGregor BA, Heath EI, Yu EY, et al. Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1\/Programmed Death Ligand 1 Therapy. J Clin Oncol. 2019;37(29):2592\u2013600. PMID: 31356140; PMCID: PMC6784850.","journal-title":"J Clin Oncol"},{"issue":"6","key":"2264_CR8","doi-asserted-by":"publisher","first-page":"102453","DOI":"10.1016\/j.clgc.2025.102453","volume":"23","author":"P Jain","year":"2025","unstructured":"Jain P, Naqvi SAA, Tripathi N, Oberoi JK, Humayun MA, Zakharia Y, et al. Real-World Outcomes of Enfortumab Vedotin and Pembrolizumab in Advanced Urothelial Carcinoma: A Multicenter Retrospective Analysis. Clin Genitourin Cancer. 2025;23(6):102453. https:\/\/doi.org\/10.1016\/j.clgc.2025.102453.","journal-title":"Clin Genitourin Cancer"},{"key":"2264_CR9","doi-asserted-by":"publisher","first-page":"232470962412573","DOI":"10.1177\/23247096241257333","volume":"12","author":"KH Chan","year":"2024","unstructured":"Chan KH, et al. Complete pathologic response with pembrolizumab and enfortumab vedotin in urothelial carcinoma of the upper urinary tract. J Investig Med High Impact Case Rep. 2024;12:23247096241257333. PMID: 38804541; PMCID: PMC11135087.","journal-title":"J Investig Med High Impact Case Rep"},{"key":"2264_CR10","doi-asserted-by":"publisher","first-page":"1608291","DOI":"10.3389\/fonc.2025.1608291","volume":"15","author":"SG Bowen","year":"2025","unstructured":"Bowen SG, et al. Case report series: Pembrolizumab and enfortumab vedotin in plasmacytoid urothelial carcinoma. Front Oncol. 2025;15:1608291. https:\/\/doi.org\/10.3389\/fonc.2025.1608291. Published 2025 Sep 8.","journal-title":"Front Oncol"},{"issue":"2","key":"2264_CR11","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s13691-025-00749-y","volume":"14","author":"F Urabe","year":"2025","unstructured":"Urabe F, et al. A case of remarkable response to combined radiation therapy, enfortumab vedotin, and pembrolizumab in metastatic urothelial carcinoma. Int Cancer Conf J. 2025;14(2):143\u20136. https:\/\/doi.org\/10.1007\/s13691-025-00749-y. Published 2025 Jan 23.","journal-title":"Int Cancer Conf J"},{"issue":"2","key":"2264_CR12","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.juro.2012.04.009","volume":"188","author":"M Rink","year":"2012","unstructured":"Rink M, Robinson BD, Green DA, et al. Impact of histological variants on clinical outcomes of patients with upper urinary tract urothelial carcinoma. J Urol. 2012;188(2):398\u2013404. https:\/\/doi.org\/10.1016\/j.juro.2012.04.009.","journal-title":"J Urol"},{"issue":"25","key":"2264_CR13","doi-asserted-by":"publisher","first-page":"3973","DOI":"10.1200\/JCO.2010.28.7052","volume":"28","author":"AB Apolo","year":"2010","unstructured":"Apolo AB, et al. Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography\/computed tomography in bladder cancer. J Clin Oncol. 2010;28(25):3973\u20138. https:\/\/doi.org\/10.1200\/JCO.2010.28.7052.","journal-title":"J Clin Oncol"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-026-02264-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-026-02264-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-026-02264-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T10:57:24Z","timestamp":1792061844000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-026-02264-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2264"],"URL":"https:\/\/doi.org\/10.1186\/s12894-026-02264-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-9120660\/v1","asserted-by":"object"}]},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"14 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Formal ethics committee approval was waived for this single-patient case report in accordance with institutional policy. Written informed consent for publication of the patient\u2019s clinical details and accompanying images was obtained from the patient. This case report was conducted in accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and accompanying images.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"246"}}